Cargando…

Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease

BACKGROUND: Disease-associated-microglia (DAM) represent transcriptionally-distinct and neurodegeneration-specific microglial profiles with unclear significance in Alzheimer’s disease (AD). An understanding of heterogeneity within DAM and their key regulators may guide pre-clinical experimentation a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rangaraju, Srikant, Dammer, Eric B., Raza, Syed Ali, Rathakrishnan, Priyadharshini, Xiao, Hailian, Gao, Tianwen, Duong, Duc M., Pennington, Michael W., Lah, James J., Seyfried, Nicholas T., Levey, Allan I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963076/ https://www.ncbi.nlm.nih.gov/pubmed/29784049 http://dx.doi.org/10.1186/s13024-018-0254-8

Ejemplares similares

Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Differential Phagocytic Properties of CD45(low) Microglia and CD45(high) Brain Mononuclear Phagocytes—Activation and Age-Related Effects
por: Rangaraju, Srikant, et al.
Publicado: (2018)

Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation
por: Rangaraju, Srikant, et al.
Publicado: (2017)

Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease
por: Donovan, Laura E, et al.
Publicado: (2013)

Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease
por: Donovan, Laura E., et al.
Publicado: (2021)

Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease
por: Higginbotham, Lenora, et al.
Publicado: (2019)

Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome
por: Dammer, Eric B., et al.
Publicado: (2022)

Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease
por: Dai, Jingting, et al.
Publicado: (2018)

Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
por: Johnson, Erik C. B., et al.
Publicado: (2018)

Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease
por: Zhou, Maotian, et al.
Publicado: (2020)

Molecular Signatures of Neuroinflammation Induced by αSynuclein Aggregates in Microglial Cells
por: Sarkar, Souvarish, et al.
Publicado: (2020)

Identification of state-specific proteomic and transcriptomic signatures of microglia-derived extracellular vesicles
por: Santiago, Juliet V., et al.
Publicado: (2023)

Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
por: Rayaprolu, Sruti, et al.
Publicado: (2020)

Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease
por: Ping, Lingyan, et al.
Publicado: (2018)

Brain Cell Type-Specific Nuclear Proteomics Is Imperative to Resolve Neurodegenerative Disease Mechanisms
por: Nelson, Ruth S., et al.
Publicado: (2022)

Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease
por: Modeste, Erica S., et al.
Publicado: (2023)

A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain
por: Umoh, Mfon E, et al.
Publicado: (2017)

U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21
por: Hales, Chadwick M, et al.
Publicado: (2014)

Quantitative Mass Spectrometry Analysis of Cerebrospinal Fluid Protein Biomarkers in Alzheimer’s Disease
por: Watson, Caroline M., et al.
Publicado: (2023)

Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
por: Ping, Lingyan, et al.
Publicado: (2020)

Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease
por: Guo, Qi, et al.
Publicado: (2021)

Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease
por: Higginbotham, Lenora, et al.
Publicado: (2020)

Machine Learning Selection of Most Predictive Brain Proteins Suggests Role of Sugar Metabolism in Alzheimer’s Disease
por: Tandon, Raghav, et al.
Publicado: (2023)

Temporal profiling of Kv1.3 channel expression in brain mononuclear phagocytes following ischemic stroke
por: Gao, Tianwen, et al.
Publicado: (2019)

Identification of Conserved Proteomic Networks in Neurodegenerative Dementia
por: Swarup, Vivek, et al.
Publicado: (2020)

Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease
por: Borkowski, Kamil, et al.
Publicado: (2021)

Coaggregation of RNA-Binding Proteins in a Model of TDP-43 Proteinopathy with Selective RGG Motif Methylation and a Role for RRM1 Ubiquitination
por: Dammer, Eric B., et al.
Publicado: (2012)

Biophysical K(v)3 channel alterations dampen excitability of cortical PV interneurons and contribute to network hyperexcitability in early Alzheimer’s
por: Olah, Viktor J, et al.
Publicado: (2022)

Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
por: Wingo, Aliza P., et al.
Publicado: (2020)

TBK1 interacts with tau and enhances neurodegeneration in tauopathy
por: Abreha, Measho H., et al.
Publicado: (2021)

Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain
por: Rayaprolu, Sruti, et al.
Publicado: (2022)

Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis
por: Wingo, Aliza P., et al.
Publicado: (2021)

Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease
por: McKenzie, Andrew T., et al.
Publicado: (2017)

Cellular Proteomic Profiling Using Proximity Labeling by TurboID-NES in Microglial and Neuronal Cell Lines
por: Sunna, Sydney, et al.
Publicado: (2023)

Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease
por: Li, Hong‐Dong, et al.
Publicado: (2021)

Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease
por: Hsieh, Yi-Chen, et al.
Publicado: (2019)

Abbreviation of the Follow-Up NIH Stroke Scale Using Factor Analysis
por: Raza, Syed Ali, et al.
Publicado: (2017)

Proteomic Analysis of Hippocampal Dentate Granule Cells in Frontotemporal Lobar Degeneration: Application of Laser Capture Technology
por: Gozal, Yair M., et al.
Publicado: (2011)

Genetic background influences the 5XFAD Alzheimer’s disease mouse model brain proteome
por: Hurst, Cheyenne D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_akvm44cvbvv1eh4dl0at53h7vv